TOP TEN perturbations for NP_741969 (Homo sapiens)

Organism: Homo sapiens
Gene: NP_741969
Selected probe(set): 205758_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NP_741969 (205758_at) across 6593 perturbations tested by GENEVESTIGATOR:

lung adenocarcinoma study 9 (metastase; lymph node) / lung adenocarcinoma study 9 (metastase; brain)

Relative Expression (log2-ratio):4.1266155
Number of Samples:3 / 6
Experimental lung adenocarcinoma study 9 (metastase; lymph node)
Metastatic tumor tissue obtained from the lymph node of patients with primary lung adenocarcinoma.
Control lung adenocarcinoma study 9 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary lung adenocarcinoma.

kidney transplantation study 11 (1 week) / normal blood sample

Relative Expression (log2-ratio):-3.7393656
Number of Samples:11 / 5
Experimental kidney transplantation study 11 (1 week)
Whole blood samples derived from kidney transplant patients 1 week post-transplantation. Samples were collected 1 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal blood sample
Blood samples derived from healthy control subjects.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):-3.4456835
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

necrotizing myopathy study 2 / inclusion body myositis study 2

Relative Expression (log2-ratio):-3.431178
Number of Samples:2 / 5
Experimental necrotizing myopathy study 2
Quadriceps femoris biopsy muscle samples from patients with clinical diagnosis of necrotizing myopathy (NM).
Control inclusion body myositis study 2
Quadriceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).

kidney transplantation study 14 (12 week) / normal B-cell (CD19+) sample

Relative Expression (log2-ratio):3.4227247
Number of Samples:3 / 5
Experimental kidney transplantation study 14 (12 week)
CD19+ B-cell samples derived from kidney transplant patients 12 weeks post-transplantation. Samples were collected 12 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal B-cell (CD19+) sample
CD19+ B-cell samples derived from healthy control subjects.

precursor-B-ALL study 3 (MLL-rearranged) / T-ALL study 3

Relative Expression (log2-ratio):-3.41955
Number of Samples:5 / 29
Experimental precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control T-ALL study 3
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):-3.4041386
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

precursor-B-ALL study 3 (hyperdiploid) / T-ALL study 3

Relative Expression (log2-ratio):-3.3420172
Number of Samples:17 / 29
Experimental precursor-B-ALL study 3 (hyperdiploid)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control T-ALL study 3
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 2 (MLL-rearranged) / T-ALL study 2

Relative Expression (log2-ratio):-3.2897625
Number of Samples:4 / 13
Experimental precursor-B-ALL study 2 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control T-ALL study 2
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Dutch Childhood Oncology Group (DCOG).

glioma study 17 (oligoastrocytoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-3.261447
Number of Samples:2 / 4
Experimental glioma study 17 (oligoastrocytoma; unsorted)
Brain cells isolated from low grade oligoastrocytoma (grade II). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.